Skip to content

Medical Cannabis as an emerging Life Sciences sector

Denmark is an international powerhouse in the pharma and advanced agriculture sector and has a well-established framework for public-private partnerships in research in the Life Sciences. The Danish medical cannabis model draws on these strengths to create a competitive, dynamic industry that continues to attract international investment.  
Icon medical cannabis
What
Life Sciences Medical cannabis
Several international companies in the industry have already set up in Denmark through joint ventures with Danish partners, based on strong but transparent regulations, availability of expertise and experience from both the pharma and horticulture sectors, strong commitment to innovation, sustainability and cutting edge automated production methods and opportunities for growth in the Danish and European markets.
Play video
Denmark uses an open-ended system with no limits on the number of cultivators, as long as high standards are maintained, and no cap on production volumes. This allows the industry to grow to a European and global scale based on high GACP and EU-GMP standards within a strict medical and pharmaceutical framework.  

Want to read more about the development scheme? 

Click here

beyond cultivation - the Medical cannabis ecosystem

In addition to cultivation, Denmark continues to attract investment in plant breeding and genetics, testing and analysis, innovative cultivation methods and technologies, extraction, formulated product development, while opportunities exist to invest in further applied research and development and clinical studies. This is the stage where medical cannabis meets the traditional pharmaceutical sector. 

Top reason for choosing Denmark for medical cannabis activities 

  • Attractive framework conditions with strong government support for medical cannabis and a transparent regulatory regime. 

  • Strong domestic medical cannabis ecosystem with close collaboration across all parts of the value chain from plant to patient.

  • Access to expertise in pharma production including availability of expertise in developing GMP compliant facilities and processes.

  • Proximity to main EU markets including Germany with excellent infrastructure for exports and transport.

  • Strong plant genetics and breeding ecosystem.

  • A well-funded healthcare system offering partial reimbursement for medical cannabis based products and an efficient retail pharmacy network for product distribution.

  • No medical cannabis production cap or quotas.

  • Access to reliable green power at a low cost.

  • Skilled horticulture and manufacturing labour force, with training modules available to reinforce skills specific to the production of medical cannabis.

Want to know more about medical cannabis industry in Denmark?

Please contact our dedicated advisors here:

Loading...